Mehr Un Nisa’s Post

New Blog: One Study Identifies Top 20 Narcolepsy Comorbidities A recently published study by Avadel Pharmaceuticals uncovers the top 20 comorbidities affecting people with narcolepsy. Surprisingly, psychiatric, sleep, and pain disorders top the list, while cardiovascular issues are notably absent. This analysis of real-world data gives valuable insights into managing narcolepsy. The top 5 narcolepsy comorbidities are: 1. Restless Legs Syndrome 2. Obstructive Sleep Apnea 3. Chronic Pain Syndrome 4. Depression 5. Migraine Read more on how this data could shape better treatment strategies for patients: https://lnkd.in/e_x9YBaX

Effective Management of Chronic TMD Pain: New Guidelines Chronic pain from temporomandibular disorders (TMD) affects millions worldwide, causing jaw pain, headaches, and more. The latest clinical practice guideline offers clear, evidence-based recommendations to manage this condition effectively. Key Recommendations: Strongly Recommended: Cognitive Behavioral Therapy (CBT) Therapist-assisted mobilization Manual trigger point therapy Supervised postural and jaw exercises Usual care (home exercises, reassurance, education) Conditionally Recommended: Manipulation therapies CBT with NSAIDs Acupuncture Not Recommended: Irreversible oral splints Discectomy NSAIDs with opioids These guidelines prioritize non-invasive, patient-centered treatments and emphasize shared decision-making. By following these guidelines, clinicians and patients can navigate TMD management more effectively, ensuring better outcomes and improved quality of life.

We love seeing new research emerging on the benefits of #clinicalhypnosis to support healing from #DGBIs. Check out this research article discussing the benefits of #gutdirectedhypnotherapy, particularly for the treatment of #IBS: https://loom.ly/GvbibaI Reach out to our team for #support! #GIPsychology #mindyourgut #GIPsych #emotionalwellbeing #mentalhealth

#Pain affects over 3.6 million Australians daily, and despite advancements in understanding, effective management remains challenging for many living with chronic conditions. In a new study from NeuRA and UNSW, researchers have reviewed the benefits of a promising area of pain research: clinical hypnosis. In a systematic review titled “Adjunctive Use of Hypnosis for Clinical Pain” recently published in PAIN Reports, researchers found consistent benefits when hypnosis is used alongside other treatments for pain reduction such as medication. Professor Dr Rodrigo Rizzo, Postdoctoral Research Fellow at NeuRA and UNSW Sydney said results were seen across chronic and acute pain: “People are very curious about hypnosis, but there is a lack of information about its effectiveness. This study suggests that hypnosis provides additional benefits for current treatments and it would be worth using clinical hypnosis to reduce pain. Compared to drug interventions, we believe that the use of clinical hypnosis is safe and low-cost and may be another option based on the patient’s preferences.” Read the full paper here: https://lnkd.in/ghenaNra

How Do Antipsychotic Medicine Affect Our Body? 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐏𝐃𝐅 https://lnkd.in/gehkpcce The antipsychotic medicine market is experiencing steady growth, driven by advancements in neuroscience, increased awareness of mental health disorders, and evolving treatment paradigms. With the global rise in cases of schizophrenia, bipolar disorder, and other psychotic conditions, the demand for innovative and effective antipsychotic drugs is higher than ever. Key trends shaping this market include: Shift Toward Atypical Antipsychotics: Atypical antipsychotics, with their lower risk of severe side effects compared to typical antipsychotics, are gaining traction. These medications also demonstrate efficacy in treating conditions beyond schizophrenia, such as depression and anxiety. Long-Acting Injectables (LAIs): LAIs are becoming the preferred option for many patients and caregivers due to improved medication adherence and reduced relapse rates. This trend is encouraging pharmaceutical companies to invest in developing new formulations. Precision Medicine and Digital Therapies: Advances in pharmacogenomics and AI-driven tools are enabling personalized treatment approaches, ensuring patients receive medications tailored to their genetic profile and clinical needs. Global Market Expansion: Emerging economies in Asia-Pacific and Latin America are witnessing rapid market growth due to increasing healthcare access, government initiatives, and destigmatization of mental health issues. However, challenges such as the high cost of novel drugs, stigma surrounding mental health, and unmet needs in drug efficacy and safety continue to be areas requiring attention. What innovations or trends in the antipsychotic medicine market excite you the most? Let's discuss! #Antipsychotics #MentalHealth #Pharmaceuticals #Biotechnology #Innovation

⚡The Modius Stress system by Neurovalens wins FDA nod and raises $2.65M. It delivers non-invasive electrical stimulation. It stimulates key areas of the brain and nervous system without the need for surgically implanted electrodes. 🔊 Dr. Jason McKeown , CEO of Neurovalens, said: “ We believe that the low risk, non-invasive therapeutic intervention offered by Neurovalens technology will be truly transformative for a range of serious medical conditions and this latest clearance moves us further towards that goal.” 🔗 https://lnkd.in/d_kC2xmM 📰 Follow Guided Solutions to receive the latest #MedTech news daily and subscribe to our weekly newsletter: https://lnkd.in/d-Baxsvq #MedicalDevices #MedicalDevice #MedicalEquipment #Medicine #Surgeons #GuidedSolutions

NOW RECRUITING people diagnosed with narcolepsy type 1 (NT1) aged 18 to 70. The purpose of this study is to research the safety and effectiveness of an investigational study drug taken orally once daily and how it may work in adults with NT1. Individuals with NT1 may be eligible for the Vibrance-1 Study. Orexin is a chemical in the brain that helps regulate the sleep/wake cycle. The investigational study drug, ALKS 2680, is an orexin-2 receptor agonist and may improve symptoms of sleep disorder, such as excessive daytime sleepiness (EDS) and cataplexy, in patients with NT1. Individuals will be evaluated by the study team to determine their eligibility to participate in this research. Each individual who qualifies will receive either the study drug or a placebo, as well as study-related medical exams and study-related laboratory tests, at no cost. Compensation for time and travel may also be available. To learn more click here: https://lnkd.in/e9rfPfwy CTR-003484

Placebo analgesia illustrates the powerful interaction between mind and body in modulating pain perception. This well-established phenomenon is reinforced by a 2024 analysis led by the University of North Carolina at Chapel Hill School of Medicine that: ⚫ Identified a specific brain pathway that could explain how positive expectations of relief alone can naturally reduce pain, in the absence of any analgesic drug or procedure ⚫ Showed increased synaptic plasticity as connections between neurons became stronger through learning, a critical factor to maintain the placebo effect  ⚫ Offers insights for therapeutic applications like cognitive behavioral therapy (CBT) in chronic and postoperative pain management Keep reading via Nature: https://lnkd.in/dir7mw3k

Positive phase 3 landmark study of a Digital Therapeutic (DTX)for Fibromyalgia! Published in The Lancet, the PROSPER-FM trial demonstrates that a 12-week, self-guided, smartphone-delivered digital acceptance and commitment therapy (ACT) program is both safe and effective for managing fibromyalgia in adults. Participants in the digital ACT group reported significantly greater improvement in their condition compared to those in the active control group, with 71% of ACT participants showing positive changes versus 22% in the control group. Statistical superiority was observed across nearly all endpoints, including the FIQ-R domains of “function,” “overall impact,” and “symptoms”; pain intensity and pain interference; the PROMIS Fatigue and Sleep Disturbance domains; the Beck Depression Inventory II (BDI II); the Psychological Inflexibility in Pain Scale (PIPS); and the Committed Action Questionnaire (CAQ-8). This opens the way to many new opportunities in non-pharmacologic therapy of fibromyalgia such as : treatment of early fibromyalgia or pre-fibromyalgia in at-risk patients (prevention), treat-to-target strategies, and more... See here the abstract: https://lnkd.in/eNBs3CFD